Health & Biotech

Dr Boreham’s Crucible: It’s glory or bust as Shareroot ramps up its social standing

August 11, 2019August 11, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Regeneus has pain sorted; now for long-term gain

August 5, 2019August 4, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Has Imugene now got the assets it needs to fast-track an acquisition?

July 29, 2019July 28, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Pharmaxis shareholders breathe easy – the FDA loves you

July 22, 2019July 22, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Nuheara’s still got its ear to the ground for a suitor… but does it actually need one?

July 14, 2019July 14, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Collingwood supporters rejoice, Orthocell can swiftly fix those missing teeth

July 7, 2019July 7, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: ‘Robust’ biotech and Kerry Stokes as a backer, so what’s holding down Patrys’ share price?

June 30, 2019June 30, 2019 | Tim Boreham

Dr Boreham’s Crucible: Next Science wants you for the war on bacteria

June 24, 2019June 24, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Expectations are high as Heramed waits to pop in the US

June 17, 2019June 16, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Medical Developments is finding ways to gain without US pain

June 10, 2019June 9, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Can Invitrocue eek out a piece of a $185m ‘humanised mice’ market?

June 3, 2019June 2, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: A lump or two, but Oncosil’s sure it has something good brewing

May 27, 2019May 26, 2019 | Tim Boreham